Person who experienced the adverse event (patient)
| Event ID | CASEID | CASEVERSION | I F COD | EVENT DT | MFR DT | INIT FDA DT | FDA DT | REPT COD | AUTH NUM | MFR NUM | MFR SNDR | LIT REF | AGE | AGE COD | AGE GRP | GNDR COD | E SUB | WT | WT COD | REPT DT | TO MFR | OCCP COD | REPORTER COUNTRY | OCCR COUNTRY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 93261115 | 9326111 | 5 | F | 20121022 | 20160622 | 20130604 | 20160701 | EXP | JP-ELI_LILLY_AND_COMPANY-JP201305008696 | ELI LILLY AND CO | 81.58 | YR | F | Y | 53.00000 | KG | 20160701 | CN | JP | JP |
Drug(s) used by person
| Event ID | CASEID | DRUG SEQ | ROLE COD | DRUGNAME | PROD AI | VAL VBM | ROUTE | DOSE VBM | CUM DOSE CHR | CUM DOSE UNIT | DECHAL | RECHAL | LOT NUM | EXP DT | NDA NUM | DOSE AMT | DOSE UNIT | DOSE FORM | DOSE FREQ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 93261115 | 9326111 | 1 | PS | CYMBALTA | DULOXETINE HYDROCHLORIDE | 1 | Oral | 20 MG, QD | Y | N | 21427 | 20 | MG | CAPSULE | QD | ||||
| 93261115 | 9326111 | 2 | I | CYMBALTA | DULOXETINE HYDROCHLORIDE | 1 | Y | N | 21427 | CAPSULE | |||||||||
| 93261115 | 9326111 | 3 | I | WARFARIN | WARFARIN | 1 | Oral | 1.5 MG, QD | Y | N | 0 | 1.5 | MG | TABLET | QD | ||||
| 93261115 | 9326111 | 4 | C | CALBLOCK | AZELNIDIPINE | 1 | Oral | 16 MG, QD | 0 | 16 | MG | TABLET | QD | ||||||
| 93261115 | 9326111 | 5 | C | HYDROCHLOROTHIAZIDE W/TELMISARTAN | HYDROCHLOROTHIAZIDETELMISARTAN | 1 | UNK, QD | 0 | TABLET | QD | |||||||||
| 93261115 | 9326111 | 6 | C | LASIX | FUROSEMIDE | 1 | Oral | 20 MG, QD | 0 | 20 | MG | TABLET | QD | ||||||
| 93261115 | 9326111 | 7 | C | ALDACTONE | SPIRONOLACTONE | 1 | Oral | 25 MG, QD | 0 | 25 | MG | TABLET | QD | ||||||
| 93261115 | 9326111 | 8 | C | CELECOX | CELECOXIB | 1 | Oral | 100 MG, BID | 0 | 100 | MG | TABLET | BID | ||||||
| 93261115 | 9326111 | 9 | C | SYMBICORT | BUDESONIDEFORMOTEROL FUMARATE DIHYDRATE | 1 | Respiratory (inhalation) | UNK, BID | 0 | INHALATION POWDER | BID |
Indications of drugs used
| Event ID | CASEID | INDI DRUG SEQ | INDI PT |
|---|---|---|---|
| 93261115 | 9326111 | 1 | Back pain |
| 93261115 | 9326111 | 2 | Pain in extremity |
| 93261115 | 9326111 | 3 | Atrial fibrillation |
| 93261115 | 9326111 | 4 | Hypertension |
| 93261115 | 9326111 | 5 | Hypertension |
| 93261115 | 9326111 | 6 | Hypertension |
| 93261115 | 9326111 | 7 | Hypertension |
| 93261115 | 9326111 | 8 | Rheumatoid arthritis |
| 93261115 | 9326111 | 9 | Asthma |
Outcome of event
| Event ID | CASEID | OUTC COD |
|---|---|---|
| 93261115 | 9326111 | OT |
Reactions reported
| Event ID | CASEID | DRUG REC ACT | PT |
|---|---|---|---|
| 93261115 | 9326111 | Drug interaction | |
| 93261115 | 9326111 | International normalised ratio increased | |
| 93261115 | 9326111 | Off label use |
Reporting Sources (this data is often not reported and may therefore be missing here)
| no results found |
Therapies reported
| Event ID | CASEID | DSG DRUG SEQ | START DT | END DT | DUR | DUR COD |
|---|---|---|---|---|---|---|
| 93261115 | 9326111 | 1 | 20121022 | 20121217 | 0 | |
| 93261115 | 9326111 | 3 | 2007 | 20121217 | 0 | |
| 93261115 | 9326111 | 8 | 2011 | 0 | ||
| 93261115 | 9326111 | 9 | 2011 | 0 |